Stocks of A-share pharmaceutical companies have experienced a big drop in prices as President Trump, who criticized high drug prices, announced plans to impose additional tariffs. How will this affect pharmaceutical companies?

On September 25th local time, Trump announced on his social media platform "Truthful Social" that starting from October 1st, the United States will implement a new round of high tariffs on multiple imported products, including a 100% tariff on patented and branded drugs. On September 26th Beijing time, pharmaceutical stocks in the A-share market experienced a significant drop. From the above policy, it can be seen that raw materials for drugs are not included in the tariff increase. If the above-mentioned tariff increase takes effect, how much will it affect Chinese pharmaceutical companies exporting to the United States? Currently, some pharmaceutical industry insiders tend to believe that the drugs targeted for tariff increases by Trump mainly involve patented drugs, while generic drugs are not included. Huahai Pharmaceutical told reporters that the company is currently not affected, as the company's formulations sold in the US are generic drugs. Haisco Pharmaceutical also stated to reporters that the current business of the company is not affected as they only produce generic drugs. Kelun Pharmaceutical also mentioned that the company is not affected. Generally speaking, patented drugs are mainly innovative drugs. An individual who has been involved in international pharmaceutical cooperation for many years told reporters that the current main export route for domestic innovative drugs is through authorization for overseas markets, without directly exporting the actual products, and domestic innovative drug companies obtain profits through profit sharing from external authorizations. Currently, among A-share pharmaceutical companies, the only one selling innovative drugs independently in the US is BeiGene. On the morning of September 26th, BeiGene's A-share stock price fell by over 4% during trading. Industry insiders told reporters that Trump's tariff policy lacks specific details, so the impact on BeiGene, which has manufacturing facilities in the US, should be limited.